A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles

Journal of Pharmaceutical Sciences

Volumn 96, Issue 12, 2007, Pages 3283-3292

  Zhang, Xue Qing ^a   Dahle, Christopher E ^b   Weiner, George J ^b   Salem, Aliasger K ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Biodegradable microparticle; CpG ODN; CpG antigen fusion molecule; Immunotherapeutic; Poly (lactic co glycolic acid); Vaccines

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; OVALBUMIN; POLYGLACTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; BIODEGRADABILITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; EMULSION; FEMALE; IMMUNE RESPONSE; MOLECULE; MOUSE; NONHUMAN; PARTICLE SIZE;

EID: 35848953467     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20978     Document Type: Article

References (40)

1. Blattman JN, Greenberg PD. 2004. Cancer immunotherapy: A treatment for the masses. Science 305:200-205.
2. Salem AK, Hung CF, Kim TW, Wu TC, Searson PC, Leong KW. 2005. Multi-component nanorods for vaccination applications. Nanotechnology 16:484-487.
3. Raychaudhuri S, Rock KL. 1998. Fully mobilizing host defense: Building better vaccines. Nature Biotechnol 16:1025-1031.
4. Hartmann G, Weiner GJ, Krieg AM. 1999. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A 96:9305-9310.
5. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM. 1997. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A 94:10833-10837.
6. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. 1996. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A 93:2879-2883.
7. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. 1995. Cpg motifs in bacterial-DNA trigger direct B-cell activation. Nature 374:546-549.
8. Krieg AM. 2003. CpG motifs: The active ingredient in bacterial extracts? Nature Med 9:831-835.
9. Diwan M, Tafaghodi M, Samuel J. 2002. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J Control Rel 85:247-262.
10. Warren TL, Bhatia SK, Acosta AM, Dahle CE, Ratliff TL, Krieg AM, Weiner GJ. 2000. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. J Immunol 165:6244-6251.
11. Zhang XQ, Dahle CE, Baman NK, Rich N, Weiner GJ, Salem AK. 2007. Potent antigen-specific immune responses stimulated by co-delivery of CpG ODN and antigens in degradable microparticles. J Immunother (in press).
12. Cho HJ, Takabayashi K, Cheng PM, Nguyen MD, Corr M, Tuck S, Raz E. 2000. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nature Biotechnol 18:509-514.
13. Salem AK, Searson PC, Leong KW. 2003. Multifunctional nanorods for gene delivery. Nature Materials 2:668-671.
14. Mutwiri GK, Nichani AK, Babiuk S, Babiuk LA. 2004. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J Control Rel 97:1-17.
15. Heit A, Schmitz F, O'Keeffe M, Staib C, Busch DH, Wagner H, Huster KM. 2005. Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. J Immunol 174:4373-4380.
16. Datta SK, Takabayashi K, Raz E. 2003. The therapeutic potential of antigen-oligonucleotide conjugates. Therapeutic Oligonucleotides, ed pp. 105-111.
17. Tighe H, Takabayashi K, Schwartz D, Van Nest G, Tuck S, Eiden JJ, Kagey-Sobotka A, Creticos PS, Lichtenstein LM, Spiegelberg HL, Raz E. 2000. Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allerg Clin Immunol 106:124-134.
18. Tighe H, Takabayashi K, Schwartz D, Marsden R, Beck L, Corbeil J, Richman DD, Eiden JJ, Spiegelberg HL, Raz E. 2000. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol 30:1939-1947.
19. Singh M, Ott G, Kazzaz J, Ugozzoli M, Briones M, Donnelly J, O'Hagan DT. 2001. Cationic microparticles are an effective delivery system for immune stimulatory CpG DNA. Pharma Res 18:1476-1479.
20. Xie H, Gursel I, Ivins BE, Singh M, O'Hagan DT, Ulmer JB, Klinman DM. 2005. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infection Immun 73:828-833.
21. Zhao Z, Leong KW. 1996. Controlled delivery of antigens and adjuvants in vaccine development. J Pharma Sci 85:1261-1270.
22. Lutsiak MEC, Kwon GS, Samuel J. 2006. Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses. J Pharm Pharmacol 58:739-747.
23. Ma J, Luo D, Kwon GS, Samuel J, Noujaim AA, Madiyalakan R. 1998. Use of encapsulated single chain antibodies for induction of anti-idiotypic humoral and cellular immune responses. J Pharma Sci 87:1375-1378.
24. Cleland JL, Barron L, Berman PW, Daugherty A, Gregory T, Lim A, Vennari J, Wrin T, Powell MF. 1996. Development of a single-shot subunit vaccine for HIV-1 .2. Defining optimal autoboost characteristics to maximize the humoral immune response. J Pharma Sci 85:1346-1349.
25. Hedley ML, Curley J, Urban R. 1998. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nature Med 4:365-368.
26. Bennewitz NL, Babensee JE. 2005. The effect of the physical form of poly(lactic-co-glycolic acid) carriers on the humoral immune response to co-delivered antigen. Biomaterials 26:2991-2999.
27. Gursel M, Tunca S, Ozkan M, Ozcengiz G, Alaeddinoglu G. 1999. Immunoadjuvant action of plasmid DNA in liposomes. Vaccine 17:1376-1383.
28. Maurer T, Heit A, Hochrein H, Ampenberger F, O'Keeffe M, Bauer S, Lipford GB, Vabulas RM, Wagner H. 2002. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur J Immunol 32:2356-2364.
29. Klinman DM, Barnhart KM, Conover J. 1999. CpG motifs as immune adjuvants. Vaccine 17:19-25.
30. Uchida T, Martin S, Foster TP, Wardley RC, Grimm S. 1994. Dose and load studies for subcutaneous and oral delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin. Pharma Res 11:1009-1015.
31. Cheng WF, Hung CF, Pai SI, Hsu KF, He LM, Ling M, Wu TC. 2002. Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects. J Biomed Sci 9:675-687.
32. Wernette CA, Smith BF, Barksdale ZL, Hecker R, Baker HJ. 2002. CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation. Vet Immunol Immunopathol 84:223-236.
33. Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, Cresswell P, Edelson RL, Saltzman WM, Hanlon DJ. 2006. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 117:78-88.
34. Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A, Bosio C, Dow S. 2006. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 176:7335-7345.
35. Ullman-Cullere MH, Foltz CJ. 1999. Body condition scoring: A rapid and accurate method for assessing health status in mice. Lab Animal Sci 49:319-323.
36. Cooper CL, Davis HL, Morris ML, Efler SM, Krieg AM, Li Y, Laframboise C, Al Adhami MJ, Khaliq Y, Seguin I, Cameron DW. 2004. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22:3136-3143.
37. Joseph A, Louria-Hayon I, Plis-Finarov A, Zeira E, Zakay-Rones Z, Raz E, Hayashi T, Takabayashi K, Barenholz Y, Kedar E. 2002. Liposomal immunostimulatory DNA sequence (ISS-ODN): An efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine 20:3342-3354.
38. Millan CLB, Weeratna R, Krieg AM, Siegrist CA, Davis HL. 1998. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci U S A 95:15553-15558.
39. Mullen GED, Giersing BK, Ajose-Popoola O, Davis HL, Kothe C, Zhou H, Aebig J, Dobrescu G, Saul A, Long CA. 2006. Enhancement of functional antibody responses to AMA1-C1/Alhydrogel (R), a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine 24:2497-2505.
40. Sandler AD, Chihara H, Kobayashi G, Zhu XY, Miller MA, Scott DL, Krieg AM. 2003. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res 63:394-399.